Colorectal Cancer (CRC)NCT07763314
Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022
An observational study of Colorectal Cancer (CRC) and Early Onset Colorectal Cancer, run by Cantonal Hospital of St. Gallen at 1 site in Switzerland.
Trial summary
The incidence of early-onset colorectal cancer (EOCRC; patients younger than 50 years) has increased worldwide over recent decades. This study aimed to provide nationwide evidence on surgically treated EOCRC in Switzerland. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Colorectal Cancer (CRC), Early Onset Colorectal Cancer
- What is being tested?
- Early-onset colorectal cancer resection and Late-onset colorectal cancer resection
- Type of treatment
- Surgery or procedure
- How many people
- 73,771 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2003to 1 Mar 2023
- How long will I take part?
- 90 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients with colorectal cancer resection in Switzerland between 2003 and 2022.
Who may be able to join
- All patients with colorectal cancer resection in Switzerland between 2003 and 2022.
Who cannot join
- incomplete case documentation
- age under 15 years
- other hospitals than general or surgical hospitals
- no index operation
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
HOCH Health Ostschweiz, Kantonsspital St.Gallen
Sankt Gallen, St.Gallen, 9000
About this study
Official title: Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022: A Retrospective National Registry Study
The incidence of early-onset colorectal cancer (EOCRC; patients younger than 50 years) has increased worldwide over recent decades. This study aimed to provide nationwide evidence on surgically treated EOCRC in Switzerland.
- Being tested
- Early-onset colorectal cancer resection, Late-onset colorectal cancer resection
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Early-onset colorectal cancer resectionProcedure or surgery
Any kind of surgical early-onset colorectal cancer resection
Late-onset colorectal cancer resectionProcedure or surgery
Any kind of surgical late-onset colorectal cancer resection
| Study group | Role | What they receive |
|---|---|---|
| Early-onset colorectal cancer | Colorectal cancer in adults younger than 50 years Receives: Procedure: Early-onset colorectal cancer resection | |
| Late-onset colorectal cancer | Colorectal cancer in adults older than 50 years Receives: Procedure: Late-onset colorectal cancer resection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of early-onset colorectal cancer
Measured: 2003 - 2022
Secondary outcomes (4)
Localization of colorectal cancer
Measured: 2003 - 2022
Sociodemographic trends
Measured: January 2003 to December 2022
Mortality
Measured: Periprocedural
Length of hospital stay
Measured: Periprocedural
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2026
- Study start1 Jan 2003
- Primary completion31 Dec 2022
- Study completion1 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Cancer (CRC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 73,771 participants (actual)
- Target duration
- 90 Days
Sponsor and investigators
- Lead sponsor
- Cantonal Hospital of St. Gallen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yanic Ammann, Cantonal Hospital of St. Gallen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07763314
- Sponsor's protocol ID
- EOCRC
- Status last verified
- Aug 2026
- First submitted
- 10 Aug 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022: A Retrospective National Registry Study
- ClinicalTrials.gov ID
- NCT07763314
- Acronym / sponsor ID
- EOCRC
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 73,771 participants (actual)
- Lead sponsor
- Cantonal Hospital of St. GallenUniversity, hospital or other
- Study start
- 1 Jan 2003 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 1 Mar 2023 (actual)
- First posted
- 13 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The incidence of early-onset colorectal cancer (EOCRC; patients younger than 50 years) has increased worldwide over recent decades. This study aimed to provide nationwide evidence on surgically treated EOCRC in Switzerland.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 90 Days
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Early-onset colorectal cancer | – | Procedure: Early-onset colorectal cancer resectionColorectal cancer in adults younger than 50 years |
| Late-onset colorectal cancer | – | Procedure: Late-onset colorectal cancer resectionColorectal cancer in adults older than 50 years |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients with colorectal cancer resection in Switzerland between 2003 and 2022.
Key inclusion criteria (1 listed)
- All patients with colorectal cancer resection in Switzerland between 2003 and 2022.
Key exclusion criteria (4 listed)
- incomplete case documentation
- age under 15 years
- other hospitals than general or surgical hospitals
- no index operation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Early-onset colorectal cancer resectionAny kind of surgical early-onset colorectal cancer resection | Procedure or surgery | Early-onset colorectal cancer |
| Late-onset colorectal cancer resectionAny kind of surgical late-onset colorectal cancer resection | Procedure or surgery | Late-onset colorectal cancer |
Primary outcome
Incidence of early-onset colorectal cancer
Time frame: 2003 - 2022
4 secondary outcomes
Localization of colorectal cancer
Time frame: 2003 - 2022
Sociodemographic trends
Time frame: January 2003 to December 2022
Mortality
Time frame: Periprocedural
Length of hospital stay
Time frame: Periprocedural
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer (CRC)
RecruitingPhase 3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
Not yet recruiting
Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach
Colorectal Cancer (CRC) Screening, CRC Screening
RecruitingPhase 1/2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Advanced Solid Tumors, Metastatic Solid Tumors
RecruitingPhase 1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Solid Tumor, Adult, Metastatic Solid Tumor
RecruitingPhase 1
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
KRAS G12C Mutation, KRAS G12S Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer (CRC) and Early Onset Colorectal Cancer, run by Cantonal Hospital of St. Gallen at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of early-onset colorectal cancer (time frame: 2003 - 2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026; AzTrials last refreshed its copy on 8 Nov 2026.